Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

Phase 4

Recruiting

• Conditions: Meningococcal Meningitis, Serogroup B; Transgender Persons; Sex Differences in Immune Response; Vaccination
• Interventions: Biological: Serogroup B meningococal vaccine

• Registration Number: NCT06832514
• Lead Sponsor: University Ghent

Brief Summary

Sexual differences are a well-established source of biological variation in immune system functioning, with men often displaying lower adaptive immune responses (e.g. antibody production) to infections and vaccinations compared to women. The impact of sex and gender on immune responses and immune functioning warrants more in-depth investigation. This study is an investigator-initiated project aimed at prospectively assessing the immune response towards a vaccine in transgender and cisgender individuals. Transgender individuals retain their chromosomal sex while undergoing a significant hormonal shift that aligns with their experienced gender. Immune responses induced by the four-component meningococcal serogroup B (4CMenB; Bexsero®) vaccine will be evaluated in transgender individuals and compared with responses observed in cisgender individuals. Both humoral and cellular immune responses induced by two doses of the 4CMenB vaccine will be quantified and analysed. This approach is expected to provide new insights into the effects of gender and sex differences on innate and adaptive immune responses.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-01-31
• Status Verified: 2025-02
• Study First Submitted: 2025-02-10
• Study First Submitted QC: 2025-02-13
• Study First Posted: 2025-02-18
• Last Update Submitted: 2025-02-25
• Last Update Posted: 2025-02-28
• Primary Completion: 2025-12-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

1. Written signed informed consent form (ICF) obtained before any study-related activities.
2. Participants aged between, and including, 18 and 40 years of age at the time of signing the ICF which equals with the time of the first study intervention.
3. Participants who are considered to be in good general health as determined by the investigator by medical evaluation including medical history andphysical examination at enrollment.
4. Participants with a BMI within the range 18.5 to 35 kg/m2 inclusive at screening.
5. POCBP (18-40 years of age) who are not pregnant or breastfeeding or planning to become pregnant during the clinical study.
6. Transgender persons need to be under stable gender-affirming hormone therapy (GAHT) for at least 6 months. Compliance needs to be documented by hormonal lab tests.
7. POCBP must have a negative urine pregnancy test at each vaccination visit (Visit 1 and Visit 5) Refer to Section 8.6.5 for Pregnancy Testing.
8. Participants who are willing and able to comply with the study procedures and are capable to comply with the requirements of the protocol (e.g. return for follow-up visits) as determined by the investigator.

Exclusion Criteria

1. Current or previous, confirmed or suspected disease caused by N. meningitidis and N. gonnorrhoea.

2. Household contact with and/or intimate exposure (e.g. sexual or saliva contact) to an individual with laboratory confirmed N. meningitidis infection during life.

3. Transgender persons in a diagnostic phase (no hormonal intervention) or undergoing treatment based on the suppression of endogenic hormones (e.g. gonadotropin releasing hormone analogues).

4. Current or previous infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV) as determined by anamnesis and medical history.

5. Past or current history of immune-mediated and/or autoimmune diseases, as indicated by the investigator, including but not limited to blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders, lupus erythematosus and associated conditions or disorders (e.g. rheumatoid arthritis, scleroderma) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).

6. History of confirmed hypersensitivity, anaphylaxis and/or other severe allergic reactions (e.g., generalized urticaria, angioedema, bronchospasm) to any component of the study vaccine or excipients (sodium chloride, histidine, sucrose, kanamycin and water for injection), medical products, or medical equipment whose use is foreseen in this study, as determined by the investigator.

7. Clinical conditions representing a contraindication for IM administration and blood draws, as judged by the investigator, e.g. thrombocytopenia or history of bleeding disorder (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties.

8. Current history of uncontrolled medical illness (unstable for the past 3 months) as indicated by investigator, e.g. hypertension, diabetes mellitus type 2.

9. Past or current history of any neurological disorder (including but not limited to: demyelinating disorder, encephalitis or myelitis of any origin, congenital neurological conditions, encephalopathies), Guillain-Barré syndrome and seizure disorders other than: 1) childhood febrile seizures, or 2) seizures that have not required treatment within the last 3 years.

10. History of asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen.

11. Active malignancy or malignancy within the past 5 years (except basocellular carcinoma (single lesions) that has been fully removed).

12. History of idiopathic urticaria within the past year.

13. Currently pregnant, breast-feeding or planning to become pregnant. Individuals with permanent infertility due to an alternate medical cause (e.g. documented bilateral oophorectomy, androgen insensitivity, gonadal dysgenesis) are excluded to participate.

14. Any other clinical condition that, in the opinion of the investigator, could compromise the participant's safety and/or compliance with the study protocol (e.g. current or recent (< 2 years ago) heavy smoking (> 20 cigarettes per day) or vaping (> 2 mL e-liquid daily, correspond with 20 cigarettes)41 , drug- or alcohol (> 15 units for cisgender men and transgender women or > 10 units or cisgender women and transgender men per week) abuse/addiction.

15. Behavioral or cognitive impairment, unstable psychiatric conditions (e.g. forced admission, suicidal thoughts in the last two year) or other psychiatric disease that, in the opinion of the investigator, may interfere with study compliance, as well as with the subject's ability and/or safety to participate in the study. Stable psychiatric conditions (e.g. under-controlled depression) will be evaluated based on the investigators judgement.

16. Donation of blood or blood products within 90 days prior to the first vaccination visit (Visit 1) until Day 56 (Visit 9).

17. Current or history of anemia and menorrhagia as determined by anamnesis and medical history.

18. Previous vaccination against any group B meningococcal vaccine (Bexsero®, Trumenba®) at any time prior to informed consent.

19. Prior receipt of a live-attenuated vaccine in the 28 days prior to administration of the 4CMenB vaccine, within 14 days for subunit or inactivated vaccines or planning to receive a vaccine in between the first and second vaccine administration, as well as 28 days following administration of the second 4CMenB vaccine dose.

20. Currently participating in another clinical study, or planning to participate in another study during the study period, or administration of any investigational drug or medical device in the 28 days prior to study vaccination.

21. Prior receipt of blood, blood-derived products or immunoglobulins in the 6 months prior to administration of the study vaccine, or planning to receive such product during the study period.

22. Chronic administration (defined as 14 consecutive days in total) of immunosuppressants (e.g. corticosteroids (PO/IV/IM) or other immune-modifying drugs (e.g. antineoplastic agents, radiotherapy) during the period starting 90 days prior to vaccination or planned administration during the study (excluding topical, inhaled and intranasal preparations and intra-articular injections). For corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent.

23. POCBP (cisgender women and transgender men) who use the following contraceptive methods will not be included in the study

    • Oral, injectable, intravaginal (i.e. intravaginal ring) or transdermal combined (oestrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation.
    • Oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation.

24. Current anti-tuberculosis prophylaxis or therapy.

25. Participants with a history of any medical conditions that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the participants when participating in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
4CMenB vaccination cisgender men	Serogroup B meningococal vaccine	The four component meningococcal serogroup B (4CMenB) vaccine will be administered to 30 cisgender men via two intramuscular injections, with a one month interval.
4CMenB vaccination cisgender women	Serogroup B meningococal vaccine	The four component meningococcal serogroup B (4CMenB) vaccine will be administered to 30 cisgender women via two intramuscular injections, with a one month interval.
4CMenB vaccination transgender women	Serogroup B meningococal vaccine	The four component meningococcal serogroup B (4CMenB) vaccine will be administered to 30 transgender women via two intramuscular injections, with a one month interval.
4CMenB vaccination transgender men	Serogroup B meningococal vaccine	The four component meningococcal serogroup B (4CMenB) vaccine will be administered to 30 transgender men via two intramuscular injections, with a one month interval.

Primary Outcome Measures

Name	Time	Method
Characterise humoral, adaptive immune responses elicited by two administrations of 4CMenB in transgender and cisgender healthy participants, aged 18 to 40 years.	From the first vaccination visit to two months post-primary vaccination	The human serum bactericidal antibody titers (hSBA) against reference strains for factor H binding protein (fHbp), Neisseria adhesin A (NadA) and Porine A (PorA) in transgender and cisgender participants.

Secondary Outcome Measures

Name	Time	Method
Characterise the cellular (CD4+ and CD8+ T cell), adaptive immune responses elicited by two administrations of 4CMenB in transgender and cisgender healthy participants, aged 18 to 40 years.	From the first vaccination visit to two months post-primary vaccination	T cell-mediated immune responses in peripheral blood mononuclear cells (PBMCs) collected at different timepoints post-vaccination in 4CMen-B vaccinated transgender and cisgender participants.

Trial Locations

Locations (1)

CEVAC, University Hospital Ghent, Belgium; 🇧🇪 Ghent, Belgium